The Regulator

16: that is how many hospitals OhioHealth already runs, the health system federal antitrust regulators quietly pushed out of a deal for a rural Ohio hospital this week in favor of a smaller rival. The Federal Trade Commission’s Bureau of Competition said September 2, 2026 that its investigation into OhioHealth’s proposed acquisition of Fairfield Medical Center, a 222-bed hospital in Lancaster, Ohio, found the deal risked “raising costs and reducing the quality of care for Ohioans” and raised concerns about how thoroughly Fairfield had searched for other buyers. FTC staff pushed Fairfield to run a broader sale process instead, which drew multiple bidders and led Fairfield to sign with Adena Health in June; that deal closed around September 1. Bureau of Competition Director Daniel Guarnera said “the Commission remains vigilant in preserving healthcare competition, especially when reviewing deals involving hospitals that serve rural communities.” Confidence: High. This run reviewed the FTC’s own statement directly. Sources: FTC Bureau of Competition Director Statement Regarding Fairfield Medical Center’s Sale to Adena Health, Adena Health acquires Fairfield Medical Center after antitrust scrutiny, Healthcare Dive.

$376 million: that is what the Centers for Medicare and Medicaid Services (CMS) sent to five states in just four days this week under its $50 billion rural health fund, with one state’s share earmarked to fight “maternity deserts.” Between September 1 and September 4, CMS’s Rural Health Transformation Program announced awards to New York ($76 million for care coordination and technology across 56 organizations and 90 projects), Indiana ($120 million, including prenatal and postpartum navigation, maternal-fetal medicine access, and a rural-focused obstetrics residency to counter its maternity deserts), Arkansas ($149.3 million for 50 projects expanding telehealth and specialty-care access, part of $209 million the state expects by September 30), Michigan ($25 million split between technology upgrades and broadband expansion), and Rhode Island ($5.48 million for healthcare career-training programs in 14 school districts). The program distributes $50 billion to all 50 states over five years under last year’s reconciliation law. Confidence: High. This run reviewed each state’s CMS press release directly. Sources: Trump Administration Announces $76 Million for New York, CMS, Trump Administration Announces $120 Million for Indiana, CMS, Trump Administration Announces $149.3 Million for Arkansas, CMS, Trump Administration Invests $25 Million in Michigan, CMS, Trump Administration Announces $5.48 Million for Rhode Island, CMS.

$6.5 million: that is what insurers actually paid out on a $1.3 billion health care fraud scheme a federal grand jury says a Georgian national helped launder, using a Pennsylvania medical equipment company as a front. The Department of Justice announced September 4, 2026 that a federal grand jury in Massachusetts indicted Erekle Gugava, 33, an undocumented immigrant from Georgia, on one count of money laundering conspiracy tied to Operation Gold Rush, which DOJ describes as the largest health care fraud case it has ever prosecuted. Prosecutors say the scheme, run by a Russia-based organization, submitted roughly $1.3 billion in fraudulent durable medical equipment claims to Medicare and private insurers using the stolen identities of elderly and disabled Americans, of which insurers paid about $6.5 million; Gugava allegedly used a Pennsylvania company, ND Medical Solutions LLC, that he nominally owned from February to July 2025, to open bank accounts and move insurance reimbursement checks to overseas accounts. Assistant Attorney General Colin M. McDonald said “fraud networks cannot function without people willing to launder and transmit their proceeds, and deterring those facilitators is essential.” Gugava faces up to 20 years in prison if convicted; the charges are allegations only. Confidence: High. This run reviewed the Department of Justice’s own press release directly. Sources: Illegal Alien from Georgia Charged for Conspiracy to Launder Proceeds of $1.3B Health Care Fraud Scheme, U.S. Department of Justice.

990: that is how many adverse-event reports the Food and Drug Administration (FDA) has logged for compounded semaglutide alone, as the agency posted a fresh round of warning letters to online peptide sellers this week. FDA posted warning letters September 1, 2026, dated August 24, to five companies, Peak Performance Peptides, Royal Peptides, NuScience Peptides, Peptide Partners, and TXP Innovations (doing business as Tex Peptides), citing them for “Unapproved New Drugs/Misbranded” over products including semaglutide, tirzepatide, retatrutide, survodutide, mazdutide, PT-141, tesamorelin, and ipamorelin blends sold online without FDA approval. As of May 31, 2026, FDA had logged 990 adverse-event reports tied to compounded semaglutide and more than 730 for compounded tirzepatide, numbers the agency says likely undercount the real total; reporting this week highlighted rising poison-control calls and hospitalizations from dosing errors. Shabbir Imber Safdar of Partnerships for Safe Medicines said “what people are being misled by is the idea that because they are being advertised, they must be legal. They’re not.” Confidence: High for FDA’s own letters and adverse-event data; Medium for the poison-control trend, which relies on secondary reporting. Sources: FDA’s Concerns with Unapproved GLP-1 Drugs Used for Weight Loss, U.S. Food and Drug Administration, FDA tracking hundreds of reports tied to compounded weight-loss drugs, unapproved peptides, WBAY.